Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects

Toxicological Sciences : an Official Journal of the Society of Toxicology
Wendy G HalpernKevin P Baker

Abstract

The tolerability, pharmacodynamic effects, and pharmacokinetics of belimumab (LymphoStat-B) were evaluated in cynomolgus monkeys. Belimumab is a fully human IgG1lambda antibody directed against B-lymphocyte stimulator (BLyS) protein. BLyS is a TNF family member that supports B-lymphocyte maturation and survival and has been implicated in the pathogenesis of autoimmune diseases and B-lymphocyte malignancies. Belimumab was developed to antagonize BLyS activity in autoimmune diseases and B-lymphocyte malignancies, where undesirable effects of B-lymphocyte activity may cause or contribute to disease. Pharmacodynamic effects of belimumab were monitored by immunophenotyping of peripheral blood. Pathology end points, including tissue immunophenotyping, are described after 13 and 26 weeks of treatment and after a 34-week treatment-free (recovery) period. Belimumab was safe and well tolerated in repeat-dose toxicology studies at 5-50 mg/kg for up to 26 weeks. Monkeys exposed to belimumab had significant decreases in peripheral blood B lymphocytes by 13 weeks of exposure, continuing into the recovery period, despite total lymphocyte counts similar to the controls. There were concomitant decreases in spleen and lymph node B-lymphocyte rep...Continue Reading

References

Jun 8, 1999·The Journal of Experimental Medicine·P SchneiderJ Tschopp
Dec 10, 1999·The Journal of Experimental Medicine·F MackayJ L Browning
Oct 4, 2000·The Journal of Experimental Medicine·R K DoS Chen-Kiang
Jul 3, 2002·Nature Reviews. Immunology·Fabienne Mackay, Jeffrey L Browning
May 15, 2004·Immunity·Flavius Martin, Andrew C Chan
Aug 6, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Svetlana Shulga-MorskayaMartin L Scott
Jan 7, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Qian GongAndrew C Chan

❮ Previous
Next ❯

Citations

May 23, 2013·Zeitschrift für Rheumatologie·R Fischer-BetzUNKNOWN Kommission Pharmakotherapie der DGRh
Jul 19, 2012·Pharmaceutical Research·Anshu MaratheDonald E Mager
Aug 9, 2012·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·S Anwar JagessarBert A 't Hart
Apr 10, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Moncef Zouali, Eugene A Uy
Jan 11, 2012·Nature Biotechnology·William Stohl, David M Hilbert
Jul 4, 2006·Nature Reviews. Drug Discovery·Jeffrey L Browning
May 3, 2011·Nature Reviews. Drug Discovery·Iñaki SanzPeter Kirkpatrick
Oct 4, 2008·Proceedings of the National Academy of Sciences of the United States of America·Jean L ScholzMichael P Cancro
Jun 5, 2008·Toxicological Sciences : an Official Journal of the Society of Toxicology·Michela CarbonattoRafael Ponce
Feb 19, 2011·Current Opinion in Rheumatology·William StohlMichael P Cancro
Feb 28, 2013·International Journal of Rheumatic Diseases·Preeta K Chugh, Bhupinder S Kalra
Feb 18, 2012·Annals of the Rheumatic Diseases·Ronald F van VollenhovenWilliam Freimuth
Jul 20, 2007·Arthritis Research & Therapy·Arne HansenThomas Dörner
Mar 9, 2011·Biologics : Targets & Therapy·Aikaterini Thanou-Stavraki, Amr H Sawalha
Oct 26, 2011·Journal of Pharmacology & Pharmacotherapeutics·Ashok K DubeyQazi M Ahmed
Sep 4, 2015·Expert Opinion on Drug Metabolism & Toxicology·Natasha P Jordan, David P D'Cruz
Aug 31, 2007·Expert Opinion on Biological Therapy·Thomas Dörner, Peter E Lipsky
Dec 28, 2012·Expert Opinion on Biological Therapy·Xingzhong Jin, Changhai Ding
Jan 7, 2014·Expert Opinion on Biological Therapy·Zozik Fattah, David A Isenberg
Jul 23, 2013·Reumatología clinica·Jaime Calvo-AlénUNKNOWN Sociedad Española de Reumatología
Apr 3, 2012·Clinical Therapeutics·Eric G Boyce, Bryan E Fusco
Oct 26, 2010·Current Opinion in Immunology·Anne Davidson
Aug 18, 2009·Cancer Treatment Reviews·Voravit RatanatharathornJoseph P Uberti
Jan 17, 2009·The Journal of Investigative Dermatology·Angela NagelRüdiger Eming
Nov 15, 2006·Clinical Lymphoma & Myeloma·Amanda Wedgwood, Anas Younes
Jan 22, 2008·The Journal of Allergy and Clinical Immunology·Marc C Levesque, E William St Clair
Nov 24, 2007·Autoimmunity Reviews·Andrea Picchianti DiamantiGuido Valesini
Nov 28, 2008·Arthritis and Rheumatism·Arumugam PalanichamyHans-Peter Tony
Jul 11, 2008·Immunological Reviews·Meera Ramanujam, Anne Davidson
Aug 11, 2011·European Journal of Immunology·Nikola S KerekovAndrey I Tchorbanov
Aug 24, 2010·Immunological Reviews·Michael J TownsendAndrew C Chan
Aug 8, 2014·Xenotransplantation·Guerard W ByrneChristopher G A McGregor
Jun 8, 2012·Arthritis and Rheumatism·Joan T MerrillUNKNOWN LBSL02/99 Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.